Kyowa Kirin Co., Ltd. (KYKOF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Kyowa Kirin Co., Ltd. (KYKOF) with AI Score 57/100 (Hold). Kyowa Kirin Co. , Ltd. is a global specialty pharmaceutical company focused on oncology, nephrology, central nervous system, and immunology. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Kyowa Kirin Co., Ltd. (KYKOF) Healthcare & Pipeline Overview
Kyowa Kirin Co., Ltd. is a global pharmaceutical company specializing in oncology, nephrology, CNS, and immunology, offering treatments like Crysvita and Romiplate. With a 13.5% profit margin and 74.2% gross margin, the company operates as a subsidiary of Kirin Holdings, focusing on innovative therapies and strategic collaborations within the healthcare sector.
Investment Thesis
Kyowa Kirin Co., Ltd. presents a compelling investment case based on its focus on specialized therapeutic areas and a robust product portfolio. With a P/E ratio of 18.79 and a dividend yield of 2.58%, the company demonstrates financial stability and shareholder returns. Key value drivers include the continued commercial success of Crysvita and Romiplate, as well as the potential approval and launch of KHK4083 in collaboration with Amgen. Growth catalysts include expanding into new geographic markets and indications, and strategic partnerships. Potential risks include regulatory challenges, competition from biosimilars, and patent expirations. The company's 13.5% profit margin and 74.2% gross margin indicate efficient operations and strong pricing power.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $6.50B reflects Kyowa Kirin's significant presence in the pharmaceutical industry.
- P/E Ratio of 18.79 indicates a reasonable valuation compared to its earnings.
- Profit Margin of 13.5% demonstrates the company's ability to generate profit from its revenue.
- Gross Margin of 74.2% showcases efficient production and strong pricing power.
- Dividend Yield of 2.58% provides a steady income stream for investors.
Competitors & Peers
Strengths
- Strong focus on specialized therapeutic areas.
- Robust product portfolio with innovative treatments.
- Strategic collaborations with other pharmaceutical companies.
- Established presence in key markets.
Weaknesses
- Reliance on a limited number of key products.
- Exposure to patent expiration risks.
- Dependence on collaborations for certain products.
- Limited presence in emerging markets compared to larger competitors.
Catalysts
- Upcoming: Potential regulatory approval and launch of KHK4083 for atopic dermatitis in collaboration with Amgen.
- Ongoing: Continued commercial success of Crysvita in existing and new markets.
- Ongoing: Expansion of Romiplate/Nplate into new indications and patient populations.
Risks
- Potential: Competition from biosimilars and generic drugs could erode market share.
- Potential: Regulatory challenges and delays in drug approvals.
- Potential: Unfavorable clinical trial results for pipeline products.
- Ongoing: Pricing pressures from healthcare payers could impact profitability.
- Ongoing: Patent expirations on key products could reduce revenue.
Growth Opportunities
- Growth opportunity 1: Expansion of Crysvita into new markets and indications represents a significant growth opportunity. Crysvita, used for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia, has demonstrated strong sales growth. Expanding its availability to additional countries and exploring new indications, such as other phosphate-related disorders, could drive further revenue growth. The market for rare bone diseases is estimated to reach $3 billion by 2028, providing a substantial addressable market for Kyowa Kirin.
- Growth opportunity 2: The successful development and commercialization of KHK4083 for atopic dermatitis, in collaboration with Amgen, presents a major growth catalyst. Atopic dermatitis is a chronic inflammatory skin disease with a high unmet need, and the market for atopic dermatitis treatments is projected to reach $12 billion by 2027. Positive Phase 3 trial results and subsequent regulatory approvals could significantly boost Kyowa Kirin's revenue and market share.
- Growth opportunity 3: Strategic partnerships and acquisitions can enhance Kyowa Kirin's product portfolio and expand its geographic reach. Collaborating with other pharmaceutical companies or acquiring promising drug candidates in its core therapeutic areas can accelerate growth and diversify its revenue streams. The company could target companies with innovative technologies or complementary product lines to strengthen its competitive position. The pharmaceutical M&A market is expected to remain active, providing opportunities for Kyowa Kirin to pursue strategic deals.
- Growth opportunity 4: Focusing on the development of novel biologics and biosimilars can drive long-term growth. Biologics are complex drugs derived from living organisms, and they often command premium prices. Developing biosimilars, which are similar versions of existing biologics, can provide a more affordable alternative and capture market share. The global biosimilars market is projected to reach $35 billion by 2025, offering a significant opportunity for Kyowa Kirin.
- Growth opportunity 5: Expanding into emerging markets, such as China and India, can fuel growth and diversify Kyowa Kirin's revenue base. These markets have large populations, increasing healthcare spending, and a growing demand for innovative medicines. Navigating the regulatory landscape and establishing a strong presence in these markets will be crucial for success. The pharmaceutical market in emerging markets is expected to grow at a faster rate than in developed markets, providing a significant growth opportunity for Kyowa Kirin.
Opportunities
- Expansion into new geographic markets.
- Development of novel biologics and biosimilars.
- Acquisition of promising drug candidates.
- Increased demand for specialized treatments in its core therapeutic areas.
Threats
- Competition from biosimilars and generic drugs.
- Regulatory challenges and delays.
- Pricing pressures from healthcare payers.
- Unfavorable clinical trial results.
Competitive Advantages
- Proprietary drug formulations and intellectual property protection.
- Strong brand recognition and reputation in specialized therapeutic areas.
- Established relationships with healthcare providers and key opinion leaders.
- Strategic collaborations with other pharmaceutical companies.
- High barriers to entry in the pharmaceutical industry due to regulatory requirements and R&D costs.
About KYKOF
Kyowa Kirin Co., Ltd., established in 1949 and headquartered in Tokyo, Japan, is a global specialty pharmaceutical company dedicated to discovering and developing innovative medicines. Originally known as Kyowa Hakko Kirin Co., Ltd., the company rebranded in June 2019 to Kyowa Kirin Co., Ltd. The company focuses on four therapeutic areas: oncology, nephrology, central nervous system (CNS), and immunology. Its diverse portfolio includes products like Crysvita, a recombinant human monoclonal antibody used for hypophosphatemia, and Romiplate/Nplate, a genetically recombinant protein for platelet production. Other key products include ABSTRAL for breakthrough cancer pain, ALLELOCK for allergies, and CONIEL for hypertension and angina pectoris. Kyowa Kirin also develops treatments for chemotherapy-induced febrile neutropenia, acute lymphoblastic leukemia, psoriasis, opioid-induced constipation, and Parkinson's disease. The company has a strategic agreement with Amgen Inc. to develop and commercialize KHK4083 for atopic dermatitis. As a subsidiary of Kirin Holdings Company, Limited, Kyowa Kirin leverages its research and development capabilities to address unmet medical needs worldwide.
What They Do
- Develops and markets pharmaceuticals for oncology, nephrology, central nervous system, and immunology.
- Offers treatments for breakthrough cancer pain, allergies, hypertension, and other diseases.
- Produces recombinant human monoclonal antibodies and genetically recombinant proteins.
- Collaborates with other pharmaceutical companies to develop and commercialize new drugs.
- Focuses on innovative therapies and addressing unmet medical needs worldwide.
- Manufactures and distributes a range of pharmaceutical products globally.
Business Model
- Develops and manufactures proprietary pharmaceutical products.
- Markets and sells these products through its own sales force and distribution network.
- Collaborates with other companies for research, development, and commercialization.
- Generates revenue through product sales and licensing agreements.
Industry Context
Kyowa Kirin operates in the global pharmaceutical industry, which is characterized by intense competition, high research and development costs, and stringent regulatory requirements. The market is driven by factors such as an aging population, increasing prevalence of chronic diseases, and technological advancements in drug discovery. Key trends include the rise of personalized medicine, the growing importance of biologics, and the increasing focus on rare diseases. Kyowa Kirin competes with major pharmaceutical companies, including ESAIY (Eisai Co., Ltd.) and GIFLF (Gilead Sciences, Inc.), focusing on specialized therapeutic areas to differentiate itself.
Key Customers
- Patients with cancer, kidney disease, neurological disorders, and immune system disorders.
- Hospitals and clinics that prescribe and administer Kyowa Kirin's products.
- Pharmacies that dispense Kyowa Kirin's medications.
- Healthcare providers who recommend and prescribe Kyowa Kirin's treatments.
Financials
Chart & Info
Kyowa Kirin Co., Ltd. (KYKOF) stock price: Price data unavailable
Latest News
No recent news available for KYKOF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for KYKOF.
Price Targets
Wall Street price target analysis for KYKOF.
MoonshotScore
What does this score mean?
The MoonshotScore rates KYKOF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Masashi Miyamoto
Unknown
Information on Masashi Miyamoto's background is not available in the provided context. His career history, education, and previous roles are unknown. Further research would be needed to provide a comprehensive biography.
Track Record: Information on Masashi Miyamoto's track record is not available in the provided context. His key achievements, strategic decisions, and company milestones under his leadership are unknown. Further research would be needed to assess his performance.
KYKOF OTC Market Information
The OTC Other tier, where KYKOF trades, represents the lowest tier of the OTC market. Companies in this tier often have limited financial disclosure and may not meet the minimum requirements for listing on higher tiers like OTCQX or OTCQB. This tier typically includes companies with limited operating history, penny stocks, and those facing financial distress. Investing in companies on the OTC Other tier carries significantly higher risks compared to those listed on major exchanges due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in KYKOF.
- Lower liquidity can lead to price volatility and difficulty in trading shares.
- OTC Other tier companies are subject to less regulatory oversight.
- Potential for fraud or manipulation is higher in the OTC market.
- Lack of analyst coverage and institutional interest can limit price appreciation.
- Verify the availability and accuracy of financial statements.
- Assess the company's business model and competitive landscape.
- Research the background and experience of the management team.
- Evaluate the company's capital structure and debt levels.
- Understand the regulatory environment and potential risks.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Subsidiary of Kirin Holdings Company, Limited.
- Focus on specialized therapeutic areas.
- Established presence in key markets.
- Partnership with Amgen Inc.
Common Questions About KYKOF
What does Kyowa Kirin Co., Ltd. do?
Kyowa Kirin Co., Ltd. is a global specialty pharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines. The company's primary therapeutic areas include oncology, nephrology, central nervous system (CNS), and immunology. Kyowa Kirin develops and markets a range of pharmaceutical products, including treatments for breakthrough cancer pain, allergies, hypertension, and various other diseases. Its key products include Crysvita, a recombinant human monoclonal antibody, and Romiplate/Nplate, a genetically recombinant protein. The company operates as a subsidiary of Kirin Holdings Company, Limited.
What do analysts say about KYKOF stock?
AI analysis is currently pending for KYKOF, so a summary of analyst consensus is not yet available. Key valuation metrics to consider include the company's P/E ratio of 18.79, profit margin of 13.5%, and dividend yield of 2.58%. Growth considerations include the potential for Crysvita and KHK4083, as well as expansion into new markets and indications. Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions. Analyst ratings and price targets will be available when the AI analysis is complete.
What are the main risks for KYKOF?
Kyowa Kirin faces several risks, including competition from biosimilars and generic drugs, which could erode market share and pricing power. Regulatory challenges and delays in drug approvals could also impact the company's pipeline and revenue growth. Unfavorable clinical trial results for pipeline products could lead to setbacks and reduced investor confidence. Pricing pressures from healthcare payers could limit profitability. Patent expirations on key products could significantly reduce revenue. Investors should carefully consider these risks before investing in KYKOF.
What are the key factors to evaluate for KYKOF?
Kyowa Kirin Co., Ltd. (KYKOF) currently holds an AI score of 57/100, indicating moderate score. Key strength: Strong focus on specialized therapeutic areas.. Primary risk to monitor: Potential: Competition from biosimilars and generic drugs could erode market share.. This is not financial advice.
How frequently does KYKOF data refresh on this page?
KYKOF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven KYKOF's recent stock price performance?
Recent price movement in Kyowa Kirin Co., Ltd. (KYKOF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Strong focus on specialized therapeutic areas.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider KYKOF overvalued or undervalued right now?
Determining whether Kyowa Kirin Co., Ltd. (KYKOF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying KYKOF?
Before investing in Kyowa Kirin Co., Ltd. (KYKOF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending and will provide additional insights.